Modality
Bispecific Ab
MOA
PD-1i
Target
SHP2
Pathway
PI3K/AKT
CSUCeliac
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ Apr 2028
Phase 1Current
NCT08844719
534 pts·CSU
2018-06→2028-04·Completed
534 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-062.0y awayPh2 Data· CSU
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Complet…
Catalysts
Ph2 Data
2028-04-06 · 2.0y away
CSU
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08844719 | Phase 1/2 | CSU | Completed | 534 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 |